---
schema_version: "secwatch.filing_event.v1"
accession: "0000014272-24-000121"
form_type: "8-K"
ticker: "BMY"
cik: "0000014272"
company_name: "BRISTOL MYERS SQUIBB CO"
filed_at: "2024-07-26T23:59:59+00:00"
generated_at: "2026-05-31T15:56:56.368645+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bristol Myers Q2 rev $12.2B (+9%), non-GAAP EPS $2.07, raises FY guidance

## Summary
- Revenues $12.2B up 9% YoY (+11% ex-FX); Growth Portfolio $5.6B up 18% (+21% ex-FX).
- GAAP EPS $0.83, non-GAAP EPS $2.07; includes $(0.04) per share net impact from IPRD and licensing.
- Raising 2024 non-GAAP guidance; U.S. approvals of Breyanzi for follicular and mantle cell lymphoma.
- Subcutaneous nivolumab under regulatory review in U.S. and E.U.
- CEO Boerner cited progress on commercial execution and pipeline advancement.

## SEC filing metadata
- accession: 0000014272-24-000121
- form_type: 8-K
- ticker: BMY
- cik: 0000014272
- company_name: BRISTOL MYERS SQUIBB CO
- filed_at: 2024-07-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/14272/000001427224000121/0000014272-24-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/14272/000001427224000121/bmy-20240726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000014272-24-000121
- JSON: https://secwatch.observer/filing/0000014272-24-000121.json
- Plain text: https://secwatch.observer/filing/0000014272-24-000121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.